Genetic Disorders in Breast and Ovarian Cancer
A special issue of Cells (ISSN 2073-4409). This special issue belongs to the section "Cell Nuclei: Function, Transport and Receptors".
Deadline for manuscript submissions: 30 June 2024 | Viewed by 1935
Special Issue Editors
2. Department of Operative and Endoscopic Gynecology, Medical University of Lodz, Lodz, Poland
Interests: ovarian cancer; carcinogenesis; immunology of solid tumors; targeted therapy; tumor markers
Interests: the molecular basis of gynecological malignant tumors; ovarian cancer carcinogenesis; non-coding RNAs; miRNAs
Special Issue Information
Dear Colleagues,
We are delighted to announce a new Special Issue on the critical topic of “Genetic Disorders in Breast and Ovarian Cancer”. This Special Issue aims to highlight the complexity of genetic landscapes in ovarian and breast cancers, especially in regard to the development, progression, and management.
Ovarian cancer continues to be a significant public health concern. The majority of ovarian cancer patients are diagnosed with advanced stages of the disease. Therefore, excessive efforts are being undertaken to improve early diagnoses and develop new management options. Recent advancements in genetic research have demonstrated the crucial role of genetic disorders in women’s malignancies. Initiatives such as The Cancer Genome Atlas (TCGA) has improved our understanding of malignant diseases, uncovering novel genetic markers and potential therapeutic targets. The use of poly (ADP-ribose) and polymerase (PARP) inhibitors has revolutionized therapeutic options in patients with BRCA mutations.
We encourage submissions of original papers or reviews that address various aspects of genetic disorders in ovarian and breast cancers, including predisposition, oncogenesis, treatment, etc. We hope that a deeper understanding of the genetic basis of breast and ovarian cancer may improve preventive strategies, personalized therapies, and enhanced patient outcomes. We will consider a broad scope of papers, however, original papers that do not have any molecular or cellular validation will not be considered for publication.
This Special Issue provides researchers with an opportunity to present the results of their studies and showcase their expertise in the field, so we eagerly anticipate your submissions.
Prof. Dr. Marek Nowak
Dr. Miłosz Wilczyński
Guest Editors
Manuscript Submission Information
Manuscripts should be submitted online at www.mdpi.com by registering and logging in to this website. Once you are registered, click here to go to the submission form. Manuscripts can be submitted until the deadline. All submissions that pass pre-check are peer-reviewed. Accepted papers will be published continuously in the journal (as soon as accepted) and will be listed together on the special issue website. Research articles, review articles as well as short communications are invited. For planned papers, a title and short abstract (about 100 words) can be sent to the Editorial Office for announcement on this website.
Submitted manuscripts should not have been published previously, nor be under consideration for publication elsewhere (except conference proceedings papers). All manuscripts are thoroughly refereed through a single-blind peer-review process. A guide for authors and other relevant information for submission of manuscripts is available on the Instructions for Authors page. Cells is an international peer-reviewed open access semimonthly journal published by MDPI.
Please visit the Instructions for Authors page before submitting a manuscript. The Article Processing Charge (APC) for publication in this open access journal is 2700 CHF (Swiss Francs). Submitted papers should be well formatted and use good English. Authors may use MDPI's English editing service prior to publication or during author revisions.
Keywords
- ovarian cancer
- breast cancer
- oncogenesis
- genetic disorders
- targeted therapy
